Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Transcription Regulation Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CDK7 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDK7/Cyclin H/MNAT1 Complex Recombinant Protein (Active Trimer) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for kinase assays. |
View CDK7 Products |
| Antigen (Mutant) | CDK7 [C312S] Mutant Recombinant Protein Covalent binding site mutation for resistance screening and selectivity profiling. |
View CDK7 Products |
| Gene Delivery | CDK7 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and rescue assays. |
View CDK7 Products |
| Benchmark Ab | Anti-CDK7 Recombinant Positive Control Sequence verified for Western Blot and Immunoprecipitation. |
View CDK7 Products |
| Validator | CDK7 siRNA Set For target knockdown validation in cell-based phenotypic assays. |
View CDK7 Products |
| Related Target A | CDK9 Transcriptional CDK partner; critical for off-target selectivity screening. |
View CDK9 Products |
| Related Target B | CDK2 Cell cycle CDK partner; critical for selectivity profiling. |
View CDK2 Products |
| Related Target C | POLR2A (RNA Polymerase II) Downstream substrate of CDK7; used to monitor pharmacological inhibition. |
View POLR2A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling against highly homologous CDK family members (CDK1, CDK2, CDK9) | Recombinant CDK complexes (CDK7/Cyclin H/MNAT1, CDK9/Cyclin T1, CDK2/Cyclin A2) strictly verified by mass spectrometry and high purity (>95%). |
| Screening covalent vs. non-covalent inhibitors | Matched wild-type CDK7 and C312S mutant proteins available to confirm covalent mechanism of action. |
| Lack of reliable positive controls for cellular assays | Clinical benchmark antibodies and sequence-verified positive control antibodies included. |
| Off-target toxicity in phenotypic screens | Validated CDK7 siRNA sets included for orthogonal genetic knockdown verification. |
Live CDK7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CDK7 therapeutics is intensifying, with major players shifting focus from pan-CDK inhibitors to highly selective, next-generation small molecules. As first-generation therapies reach the clinic, the next wave of R&R is targeting covalent inhibition strategies and combination regimens to overcome transcription-associated oncogenic drivers in refractory solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Covalent Small Molecule | Syros Pharmaceuticals, Carrick Therapeutics | Breast Cancer (HR+/HER2-), Ovarian Cancer, SCLC | Covalent binding verification (Need CDK7 C312S mutant and wild-type kinase complexes) |
| Non-Covalent Small Molecule | AstraZeneca, Loxo Oncology | Advanced Solid Tumors, Prostate Cancer | Selectivity assays against CDK1/2/9 (Need highly pure CDK family panels) |
| PROTAC / Degraders | Academic / Biotech early stage | Hematological Malignancies | Target degradation kinetics (Need CDK7 Lentivirus for stable cell line reporter assays) |